Preface – iwCLL 2023 © author's own – Kiyomi Mashima MD, PhD, Medical Oncology, CLL Center, Dana-Farber Cancer Institute, Boston, MA, USA, Department of Medicine, Harvard Medical School, Boston, MA, USA Dear Colleagues, The 20th International Workshop on chronic lymphocytic leukemia (iwCLL) was held in Boston, USA, and virtually from 6th–9th October 2023. This conference featured 11 sessions committed to discussing the management of patients with CLL world-wide and to creating progress re

Continuous BTK inhibition and combination regimens: present and future Agents of outstanding efficacy Inhibitors of Bruton tyrosine kinase (BTK) have changed the standards of care in the setting of chronic lymphocytic leukemia (CLL). However, they do not eliminate leukemia, and undetectable residual disease is only very rarely achieved.

Long-term results and other findings from clinical trials MURANO: 7-year data and retreatment substudy Fixed-duration venetoclax plus rituximab (VenR; n = 194) was tested against bendamustine plus rituximab (BR) for six months (n = 195) in the global, open-label, randomized phase III MURANO study that enrolled patients with relapsed/refractory CLL. In the experimental arm, 6 cycles of rituximab were administered, and venetoclax monotherapy was taken for a total of 24 months. Indeed, VenR gav

Overcoming resistance to targeted inhibitors Subclonal mutations on covalent BTK inhibitor treatment As covalent BTK inhibitors have been in use for the treatment of CLL in clinical practice for an extended period of time, different resistance mutations are being observed.

CLL treatment in the real world: insights from across the globe Second- and later-line therapies in the USA The analysis reported by Davids et al. at iwCLL 2023 examined the characteristics, treatment patterns and outcomes of a cohort of 1,102 real-world US patients with CLL receiving two or more lines of therapy [1].

Issues in the management of CLL patients from an international point of view Insights into patient needs The CLL Advocates Network (CLLAN) is a global network of patient advocacy organizations dedicated to improving the outcomes of patients with CLL through collaboration with national organizations.

Interview: Different perspectives on how to define success in CLL ©Peter MacCallum Cancer Centre  - John F. Seymour, MBBS, FRACP, PhD, Department of Haematology, Royal Melbourne Hospital, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Victoria, Australia Fortunately, the landscape of CLL treatment has dramatically transformed over the last ten years, shifting from chemotherapy to new targeted therapies. These advancements have not only extended patients' lifespans b